Fastest Growing Stocks
KNSA is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Price & Overview
NASDAQ:KNSA • GB00BRXB0C07
Current stock price
43.04 USD
+0.59 (+1.39%)
At close:
42.9 USD
-0.14 (-0.33%)
Pre-Market:
The current stock price of KNSA is 43.04 USD. Today KNSA is up by 1.39%. In the past month the price decreased by -4.23%. In the past year, price increased by 101.45%.
KNSA Key Statistics
52-Week Range21.25 - 50.03
Current KNSA stock price positioned within its 52-week range.
1-Month Range41.49 - 50.03
Current KNSA stock price positioned within its 1-month range.
- Market Cap
- 3.294B
- P/E
- 58.16
- Fwd P/E
- 39.02
- EPS (TTM)
- 0.74
- Dividend Yield
- N/A
KNSA Stock Performance
Today
+1.39%
1 Week
-6.21%
1 Month
-4.23%
3 Months
+1.99%
Longer-term
6 Months +10.56%
1 Year +101.45%
2 Years +129.92%
3 Years +300.37%
5 Years +161.48%
10 Years N/A
KNSA Stock Chart
KNSA Stock Screens
KNSA currently appears in the following ChartMill screener lists.
Revenue Growth Leaders
KNSA is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
Strong Buy Rated Stocks
KNSA is part of our Strong Buy Rated Stocks screen, indicating it has a strong buy ratings from analysts and supporting business quality.
CAN SLIM Stocks
KNSA is part of our CAN SLIM stock list, indicating it is suited for high growth momentum investing and is a technical leader.
Highest Analyst Upside Stocks
KNSA is part of our highest analyst upside stock list, indicating analysts have a price target way above the current price.
High EPS Growth Stocks
KNSA occurs in our High EPS Growth Stocks screen list, indicating it is profitable, healthy and showing strong recent EPS growth.
KNSA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to KNSA. When comparing the yearly performance of all stocks, KNSA is one of the better performing stocks in the market, outperforming 90.02% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
KNSA Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to KNSA. KNSA scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
KNSA Earnings
On April 21, 2026 KNSA reported an EPS of 0.17 and a revenue of 202.13M. The company missed EPS expectations (-55.48% surprise) and beat revenue expectations (1.62% surprise).
Next Earnings DateJul 27, 2026
Last Earnings DateApr 21, 2026
PeriodQ4 / 2025
EPS Reported$0.17
Revenue Reported202.127M
EPS Surprise -55.48%
Revenue Surprise 1.62%
KNSA Forecast & Estimates
14 analysts have analysed KNSA and the average price target is 56.97 USD. This implies a price increase of 32.38% is expected in the next year compared to the current price of 43.04.
For the next year, analysts expect an EPS growth of 49.06% and a revenue growth 35.13% for KNSA
Analysts
Analysts85.71
Price Target56.97 (32.37%)
EPS Next Y49.06%
Revenue Next Year35.13%
KNSA Groups
Sector & Classification
KNSA Financial Highlights
Over the last trailing twelve months KNSA reported a non-GAAP Earnings per Share(EPS) of 0.74. The EPS increased by 221.31% compared to the year before.
Income Statements
Revenue(TTM)677.56M
Net Income(TTM)59.01M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.71% | ||
| ROA | 7.73% | ||
| ROE | 10.4% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%241.67%
Sales Q2Q%64.95%
EPS 1Y (TTM)221.31%
Revenue 1Y (TTM)60.09%
KNSA Ownership
Ownership
Inst Owners103.34%
Shares76.54M
Float44.20M
Ins Owners3.29%
Short Float %9.25%
Short Ratio6.7
KNSA Latest News, Press Relases and Analysis
9 days ago - By: Chartmill
20 days ago - By: Chartmill
KNSA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 354.636B | ||
| AMGN | AMGEN INC | 15.15 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.79 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.5 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KNSA
Company Profile
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Company Info
IPO: 2018-05-24
KINIKSA PHARMACEUTICALS INTE
23 Old Bond Street, Floor 3
London HM11 GB
CEO: Sanj K. Patel
Employees: 366
KINIKSA PHARMACEUTICALS INTE / KNSA FAQ
Can you describe the business of KINIKSA PHARMACEUTICALS INTE?
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
What is the stock price of KINIKSA PHARMACEUTICALS INTE today?
The current stock price of KNSA is 43.04 USD. The price increased by 1.39% in the last trading session.
Does KNSA stock pay dividends?
KNSA does not pay a dividend.
What is the ChartMill rating of KINIKSA PHARMACEUTICALS INTE stock?
KNSA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
How is the market expecting KNSA stock to perform?
14 analysts have analysed KNSA and the average price target is 56.97 USD. This implies a price increase of 32.38% is expected in the next year compared to the current price of 43.04.
Can you provide the growth outlook for KINIKSA PHARMACEUTICALS INTE?
The Revenue of KINIKSA PHARMACEUTICALS INTE (KNSA) is expected to grow by 35.13% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does KINIKSA PHARMACEUTICALS INTE (KNSA) report earnings?
KINIKSA PHARMACEUTICALS INTE (KNSA) will report earnings on 2026-07-27.